Optimum News

Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD

Ensifentrine delivery via MDI inhalers could dramatically expand clinical utility and commercial opportunity LONDON, June 04, 2019 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a … Continue reading “Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD”

By Optimum

Be The Match BioTherapies® and Kiadis Pharma Announce Strategic Collaboration To Accelerate Patient Access To Haploidentical Stem Cell Therapies

22.MAY 2019 AT 18:00:00 CET Collaboration will support Phase III clinical trial of cell therapy product ATIR101(TM) for blood cancers MINNEAPOLIS & AMSTERDAM, May 22, 2019 – Be The Match BioTherapies®, an … Continue reading “Be The Match BioTherapies® and Kiadis Pharma Announce Strategic Collaboration To Accelerate Patient Access To Haploidentical Stem Cell Therapies”

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH